CSIMarket



Bristol myers Squibb Company  (BMY)
Other Ticker:  
 
 

BMY's Income from Cont. Operations Growth by Quarter and Year

Bristol Myers Squibb's Income from Cont. Operations results by quarter and year




BMY Income from Cont. Operations (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
IV Quarter December - 2,372.00 -10,027.00 -1,060.00
III Quarter September - 1,552.00 1,878.00 1,366.00
II Quarter June - 1,061.00 -80.00 1,439.00
I Quarter March 1,283.00 2,029.00 -766.00 1,715.00
FY   1,283.00 7,014.00 -8,995.00 3,460.00



BMY Income from Cont. Operations first quarter 2022 Y/Y Growth Comment
Bristol Myers Squibb Company reported fall in Income from Cont. Operations in the first quarter 2022 by -36.77% to $ 1,283.00 millions, from the same quarter in 2021.
The drop in the first quarter 2022 Bristol Myers Squibb Company's Income from Cont. Operations compares unfavorably to the Company's average Income from Cont. Operations growth of 7.22%.

Looking into first quarter 2022 results within Major Pharmaceutical Preparations industry 40 other companies have achieved higher Income from Cont. Operations growth. While Bristol Myers Squibb Company' s Income from Cont. Operations drop of -36.77% ranks overall at the positon no. 1689 in the first quarter 2022.




BMY Income from Cont. Operations ( Y/Y Growth %) 2022
2021 2020 2019
IV Quarter December - - - -
III Quarter September - -17.36 % 37.48 % -28.56 %
II Quarter June - - - 276.7 %
I Quarter March -36.77 % - - 14.72 %
FY   - - - -30.06 %

Financial Statements
Bristol Myers Squibb's first quarter 2022 Income from Cont. Operations $ 1,283.00 millions BMY's Income Statement
Bristol Myers Squibb's first quarter 2021 Income from Cont. Operations $ 2,029.00 millions Quarterly BMY's Income Statement
New: More BMY's historic Income from Cont. Operations Growth >>


BMY Income from Cont. Operations (Quarter on Quarter Growth %)

2022
2021 2020 2019
IV Quarter December - 52.84 % - -
III Quarter September - 46.28 % - -5.07 %
II Quarter June - -47.71 % - -16.09 %
I Quarter March -45.91 % - - 48.1 %
FY (Year on Year)   - - - -30.06 %




Income from Cont. Operations first quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #41
Healthcare Sector #136
Overall #1689

Income from Cont. Operations Y/Y Growth Statistics
High Average Low
261.39 % 7.22 % -76.8 %
(Sep 30 2018)   (Dec 31 2017)
Income from Cont. Operations first quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #41
Healthcare Sector #136
Overall #1689
Income from Cont. Operations Y/Y Growth Statistics
High Average Low
261.39 % 7.22 % -76.8 %
(Sep 30 2018)   (Dec 31 2017)

Income from Cont. Operations by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Bristol Myers Squibb's Q/Q Income from Cont. Operations Growth


Income from Cont. Operations Q/Q Growth Statistics
High Average Low
9123.08 % 179.56 % -98.22 %
(Mar 31 2015)   IV. Quarter


BMY's I. Quarter Q/Q Income from Cont. Operations Comment
In the I. Quarter 2022 Bristol Myers Squibb Company realized fall in Income from Cont. Operations from the forth quarter by -45.91% to $ 1,283.00 millions, from $ 2,372.00 millions released in the previous quarter.

Within Major Pharmaceutical Preparations industry 25 other companies have achieved higher Income from Cont. Operations quarter on quarter growth. While Bristol Myers Squibb's Income from Cont. Operations growth quarter on quarter, overall rank is 1471.


Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #26
Healthcare Sector #107
Overall #1471
Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #26
Healthcare Sector #107
Overall #1471
Income from Cont. Operations Q/Q Growth Statistics
High Average Low
9123.08 % 179.56 % -98.22 %
(Mar 31 2015)   IV. Quarter


BMY's I. Quarter Q/Q Income from Cont. Operations Comment
In the I. Quarter 2022 Bristol Myers Squibb Company disclosed fall in Income from Cont. Operations from the forth quarter by -45.91% to $ 1,283.00 millions, from $ 2,372.00 millions released in the previous reporting period.

Within Major Pharmaceutical Preparations industry 25 other companies have achieved higher Income from Cont. Operations quarter on quarter growth. While Bristol Myers Squibb's Income from Cont. Operations growth quarter on quarter, overall rank is 1471.


Bristol Myers Squibb's 12 Months Income from Cont. Operations Growth Year on Year


Income from Cont. Operations TTM Growth

12 Months Ending
(Mar 31 2022)
12 Months Ending
(Dec 31 2021)
12 Months Ending
(Sep 30 2021)
12 Months Ending
(Jun 30 2021)
12 Months Ending
(Mar 31 2021)
Cumulative Income from Cont. Operations 12 Months Ending $ 6,268.00 $ 7,014.00 $ -5,385.00 $ -5,059.00 $ -6,200.00
Y / Y Income from Cont. Operations Growth (TTM) - - - - -
Year on Year Income from Cont. Operations Growth Overall Ranking # # # # #
Seqeuential Income from Cont. Operations Change (TTM) -10.64 % - - - -
Seq. Income from Cont. Operations Growth (TTM) Overall Ranking # 1689 # 0 # 0 # 0 # 0




Cumulative Income from Cont. Operations growth Comment
In the Mar 31 2022 period, Bristol Myers Squibb had cumulative twelve months Income from Cont. Operations of $ 6,268 millions compare to loss from continued operations of $ -6,200 millions a year ago.

Bristol myers Squibb Company achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
261.39 %
7.22 %
-76.8 %
 

Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall # 0

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
1440.59 %
51.36 %
-91.14 %
(Jun 30 2019)   IV. Quarter


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry # 41
Sector # 136
S&P 500 # 1689
Cumulative Income from Cont. Operations growth Comment
In the Mar 31 2022 period, Bristol Myers Squibb had cumulative twelve months Income from Cont. Operations of $ 6,268 millions compare to loss from continued operations of $ -6,200 millions a year ago.

Bristol myers Squibb Company achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
261.39 %
7.22 %
-76.8 %
 


Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall # 0

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
1440.59 %
51.36 %
-91.14 %
(Jun 30 2019)   IV. Quarter


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry # 41
Sector # 136
S&P 500 # 1689




Other Income from Cont. Operations Growth
Major Pharmaceutical Preparations Industry Income from Cont. Operations Growth Trends and Statistics
Healthcare Sector Income from Cont. Operations Growth Statistics
Income from Cont. Operations Growth Trends for overall market
BMY's Income from Cont. Operations Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Income from Cont. Operations Growth
Lowest Ranking Income from Cont. Operations Growth
Income from Cont. Operations Growth for BMY's Competitors
Income from Cont. Operations Growth for Bristol Myers Squibb's Suppliers
Income from Cont. Operations Growth for BMY's Customers

You may also want to know
BMY's Annual Growth Rates BMY's Profitability Ratios BMY's Asset Turnover Ratio BMY's Dividend Growth
BMY's Roe BMY's Valuation Ratios BMY's Financial Strength Ratios BMY's Dividend Payout Ratio
BMY's Roa BMY's Inventory Turnover Ratio BMY's Growth Rates BMY's Dividend Comparisons



Companies with similar Income from Cont. Operations fall for the quarter ending Mar 31 2022 within Healthcare SectorY/Y Change %Income from Cont. Operations for the quarter ending Mar 31 2022
Chemed Corporation-1.88%$ -1.882 millions
Biomx Inc -2.77%$ -2.773 millions
Ironwood Pharmaceuticals inc -2.82%$ -2.818 millions
Corcept Therapeutics Inc-2.85%$ -2.847 millions
Msa Safety Inc-2.89%$ -2.891 millions
Merit Medical Systems Inc-3.77%$ -3.769 millions
Addus Homecare Corporation-4.77%$ -4.767 millions
Idexx Laboratories Inc-5.05%$ -5.054 millions
Hca Healthcare Inc -7.28%$ -7.278 millions
National Research Corporation-7.51%$ -7.506 millions
Amgen Inc -10.33%$ -10.328 millions
Organon and Co -11.90%$ -11.899 millions
Regeneron Pharmaceuticals Inc -12.71%$ -12.706 millions
Intuitive Surgical Inc -15.12%$ -15.119 millions
Apollo Medical Holdings Inc -16.50%$ -16.496 millions
Encompass Health Corporation-17.09%$ -17.093 millions
Molecular Templates Inc -19.30%$ -19.296 millions
Royalty Pharma Plc-19.43%$ -19.434 millions
Natus Medical Inc-20.58%$ -20.576 millions
Fulgent Genetics Inc -23.49%$ -23.486 millions
Quest Diagnostics Inc-23.88%$ -23.878 millions
Hologic Inc-26.49%$ -26.488 millions
Integra Lifesciences Holdings Corp-27.52%$ -27.521 millions
Universal Health Services Inc -27.77%$ -27.765 millions
National Healthcare Corp-27.97%$ -27.966 millions
Incyte Corp-29.03%$ -29.033 millions
Davita Inc -29.44%$ -29.439 millions
Reynolds Consumer Products Inc -29.73%$ -29.730 millions
Semler Scientific inc -31.11%$ -31.105 millions
Align Technology inc -32.98%$ -32.977 millions


       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

FOFN's Profile

Stock Price

FOFN's Financials

Business Description

Fundamentals

Charts & Quotes

FOFN's News

Suppliers

FOFN's Competitors

Customers & Markets

Economic Indicators

FOFN's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071